Nuzenio

Heart Disease Therapies

Heart Disease Therapies news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 16 latest news signals 14 publisher sources 100/100 entity strength

Latest news

Unapproved in US for decades, levosimendan stumbles in phase 3 as Tenax eyes narrow FDA path - Fierce PharmaFierce Pharma · Mon, 10 Aug 2026 20:40:16 GMTStudy Points to High Blood Pressure as a Key Factor in Rising Heart Disease Rates - Mega Doctor NewsMega Doctor News · Mon, 10 Aug 2026 18:34:20 GMTScientific statement reframes cardiovascular care for older patients with cognitive impairment and frailty - News-MedicalNews-Medical · Mon, 10 Aug 2026 17:20:00 GMTAll ECU Health hospitals receive Get With The Guidelines® awards for fourth consecutive year - ECU HealthECU Health · Mon, 10 Aug 2026 17:05:19 GMTDid Novo’s phase 3 flop kill the inflammation hypothesis in heart disease? - Pharma VoicePharma Voice · Mon, 10 Aug 2026 13:30:27 GMTTenax Therapeutics Announces Topline Results from Phase 3 LEVEL Clinical Trial of TNX-103 in Patients with PH-HFpEF - Investing News NetworkInvesting News Network · Mon, 10 Aug 2026 12:54:11 GMTIs Repatha a Statin? Plus Common Side Effects of the Cholesterol Drug - Woman's WorldWoman's World · Mon, 10 Aug 2026 11:50:17 GMTHeart failure drug from Tenax Therapeutics fails in pivotal study - STATSTAT · Mon, 10 Aug 2026 11:43:53 GMT

Timeline

Mon, 10 Aug 2026 20:40:16 GMTUnapproved in US for decades, levosimendan stumbles in phase 3 as Tenax eyes narrow FDA path - Fierce Pharma
Mon, 10 Aug 2026 18:34:20 GMTStudy Points to High Blood Pressure as a Key Factor in Rising Heart Disease Rates - Mega Doctor News
Mon, 10 Aug 2026 17:20:00 GMTScientific statement reframes cardiovascular care for older patients with cognitive impairment and frailty - News-Medical
Mon, 10 Aug 2026 17:05:19 GMTAll ECU Health hospitals receive Get With The Guidelines® awards for fourth consecutive year - ECU Health
Mon, 10 Aug 2026 13:30:27 GMTDid Novo’s phase 3 flop kill the inflammation hypothesis in heart disease? - Pharma Voice
Mon, 10 Aug 2026 12:54:11 GMTTenax Therapeutics Announces Topline Results from Phase 3 LEVEL Clinical Trial of TNX-103 in Patients with PH-HFpEF - Investing News Network

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Heart Disease Therapies.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

14 distinct publisher/source names are currently connected to this entity page.